SCHEMBL6905798

SCHEMBL6905798

CC1(C=CC2(C(F)(F)F)NC(=O)Nc3ccc(Cl)cc32)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 3/20 0.48
AKR1B1 P15121 4/20 0.40
CYP46A1 Q9Y6A2 3/20 0.38
PGR P06401 2/20 0.37
NR1I2 O75469 1/20 0.37
NR3C1 P04150 1/20 0.37
ADRB1 P08588 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
MAPT P10636 1/20 0.37
CNR1 P21554 1/20 0.37
SLC6A2 P23975 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
MAPK1 P28482 1/20 0.37
AGTR1 P30556 1/20 0.37
CCKBR P32239 1/20 0.37
PPARG P37231 1/20 0.37
OPRK1 P41145 1/20 0.37
SLC6A3 Q01959 1/20 0.37
PDE4D Q08499 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6905802 1.00 PDE7A (0.48) PDE7AAKR1B1CYP46A1PGRNR1I2
SCHEMBL6905795 1.00 PDE7A (0.48) PDE7AAKR1B1CYP46A1PGRNR1I2
SCHEMBL29393057 0.81 PDE7A (0.45) PDE7AAKR1B1CYP46A1PGRNR1I2
SCHEMBL4088810 0.81 PDE7A (0.45) PDE7AAKR1B1CYP46A1PGRNR1I2
SCHEMBL1046528 0.81 PDE7A (0.45) PDE7AAKR1B1CYP46A1PGRNR1I2
SCHEMBL1079634 0.81 PDE7A (0.45) PDE7AAKR1B1CYP46A1PGRNR1I2
SCHEMBL6905458 0.71 PDE7A (0.48) PDE7AAKR1B1CYP46A1PGRNR1I2
SCHEMBL29378147 0.66 PDE7A (0.41) PDE7AAKR1B1CYP46A1PGRNR1I2
SCHEMBL1079633 0.64 PDE7A (0.45) PDE7AAKR1B1CYP46A1PGRNR1I2
SCHEMBL1046527 0.64 PDE7A (0.45) PDE7AAKR1B1CYP46A1PGRNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063734-A1 4,4-Disubstituted-3,4-dihydro-2 (1H)-quinazoliniones useful as HIV reverse transcriptase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-04-01 US claimed
US-20040063734-A1 4,4-Disubstituted-3,4-dihydro-2 (1H)-quinazoliniones useful as HIV reverse transcriptase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063734-A1 4,4-Disubstituted-3,4-dihydro-2 (1H)-quinazoliniones useful as HIV reverse transcriptase inhibitors NQO2, DPYD, QTRT1 PDE7A 324/4885AKR1B1 750/4885CYP46A1 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.